Plus Therapeutics (PSTV) said Friday that its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.
The clinical-stage company said that the study showed no dose-limiting toxicity, and that the majority of adverse events were unrelated to the treatment.
Plus Therapeutics said that, based on these results, it is currently enrolling patients in a mid-stage trial at medical centers.
Shares of the company climbed as much as 40% in recent premarket activity on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.